The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib

Haematologica. 2006 Jan;91(1):137-8.

Abstract

Imatinib mesylate has become the gold standard front-line treatment of chronic myelogenous leukemia through its ability to inhibit ABL tyrosine kinase. Resistance to this inhibition may occur. We investigated the role of the K247R polymorphism in persistent sensitivity.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzamides
  • Drug Resistance, Neoplasm / genetics*
  • Humans
  • Imatinib Mesylate
  • Mutation, Missense
  • Pharmacogenetics
  • Piperazines / pharmacology*
  • Protein-Tyrosine Kinases / genetics
  • Proto-Oncogene Proteins c-abl / genetics*
  • Pyrimidines / pharmacology*

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-abl